Trademark: 87837595
Word
AW ACTAVIS
Status
Dead
Status Code
606
Status Date
Monday, June 20, 2022
Serial Number
87837595
Mark Type
3000
Filing Date
Friday, March 16, 2018
Published for Opposition
Tuesday, March 19, 2019
Abandoned Date
Monday, June 20, 2022

Trademark Owner History
ACTAVIS HOLDCO US, INC - Owner At Publication

Classifications
5 Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, neurological disorders, neurodegenerative disorders, and depression, antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic, anti-inflammatory ointments; ocular wetting solutions, artificial tears and formulations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
The mark consists of the word "ACTAVIS" below the letters "A" and "W", which appear in an intertwined fanciful lettering style that resembles a horizontal zig-zag line or a coil, which are both displayed in the color white. The word "ACTAVIS" and the letters "A" and "W" are centered within a rectangle displayed in the color gray.
The color(s) gray and white is/are claimed as a feature of the mark.

Trademark Events
Jun 21, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Jun 20, 2022
Abandonment - No Use Statement Filed
Nov 17, 2021
Notice Of Approval Of Extension Request E-Mailed
Nov 16, 2021
Sou Extension 5 Granted
Nov 9, 2021
Sou Extension 5 Filed
Nov 16, 2021
Case Assigned To Intent To Use Paralegal
Nov 9, 2021
Teas Extension Received
May 18, 2021
Notice Of Approval Of Extension Request E-Mailed
May 14, 2021
Sou Extension 4 Granted
May 14, 2021
Sou Extension 4 Filed
May 14, 2021
Teas Extension Received
Nov 7, 2020
Notice Of Approval Of Extension Request E-Mailed
Nov 5, 2020
Sou Extension 3 Granted
Nov 5, 2020
Sou Extension 3 Filed
Nov 5, 2020
Teas Extension Received
May 14, 2020
Notice Of Approval Of Extension Request E-Mailed
May 12, 2020
Sou Extension 2 Granted
May 12, 2020
Sou Extension 2 Filed
May 12, 2020
Teas Extension Received
Jul 13, 2019
Notice Of Approval Of Extension Request E-Mailed
Jul 11, 2019
Sou Extension 1 Granted
Jul 11, 2019
Sou Extension 1 Filed
Jul 11, 2019
Teas Extension Received
May 14, 2019
Noa E-Mailed - Sou Required From Applicant
Mar 19, 2019
Official Gazette Publication Confirmation E-Mailed
Mar 19, 2019
Published For Opposition
Feb 27, 2019
Notification Of Notice Of Publication E-Mailed
Feb 11, 2019
Assigned To Lie
Jan 26, 2019
Approved For Pub - Principal Register
Jan 9, 2019
Teas/Email Correspondence Entered
Jan 9, 2019
Correspondence Received In Law Office
Jan 9, 2019
Teas Response To Office Action Received
Jul 9, 2018
Notification Of Non-Final Action E-Mailed
Jul 9, 2018
Non-Final Action E-Mailed
Jul 9, 2018
Non-Final Action Written
Jun 27, 2018
Assigned To Examiner
Mar 24, 2018
Notice Of Design Search Code E-Mailed
Mar 23, 2018
New Application Office Supplied Data Entered In Tram
Mar 20, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24